» Articles » PMID: 34194968

Prosthesis or Osteosynthesis for the Treatment of a Pathological Hip Fracture? A Nationwide Registry-based Cohort Study

Overview
Journal J Bone Oncol
Publisher Elsevier
Date 2021 Jul 1
PMID 34194968
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: How endoprosthetic replacement compares to osteosynthesis in the treatment of pathologic hip fractures as far as functional outcome and use of healthcare resources is concerned remains largely unknown. We aimed to investigate this in a nationwide registry.

Methods: We analyzed the functional outcome after surgery for a pathological fracture of the hip in terms of post-operative pain and ambulatory capacity. The preferred surgical method depending on the level of the treating unit was also examined. Furthermore, we documented the length of hospital stay and the patterns of discharge and compared them between these two methods.

Results: Patients operated with an endoprosthesis reported significantly lower pain at follow-up. Both methods (endoprosthetic replacement and osteosynthesis) were equally effective in restoring the ambulatory capacity and demanded a similar length of stay in hospital. Orthopaedic surgeons working in hospitals with dedicated sarcoma teams were more likely to use a prosthesis rather than osteosynthesis, when compared to surgeons working at other university hospitals or emergency hospitals.

Conclusion: Endoprosthetic replacement results in a better functional outcome in terms of post-operative pain without consuming more healthcare resources. Orthopaedic surgeons working in hospitals with sarcoma centers are more likely to use prostheses as compared to surgeons working at hospitals where dedicated musculoskeletal oncology teams are not available.

Citing Articles

Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.

Mehnert E, Moller F, Hofbauer C, Weidlich A, Winkler D, Troost E BMC Cancer. 2024; 24(1):1431.

PMID: 39574021 PMC: 11580346. DOI: 10.1186/s12885-024-13170-0.


Investigation of the predictive value of systemic immune inflammation index (SII) and prognostic nutritional index (PNI) on mortality in patients with endoprosthesis after hip fracture.

Yilmaz S, Kurt M, Dulgeroglu T Medicine (Baltimore). 2024; 103(18):e38063.

PMID: 38701306 PMC: 11062679. DOI: 10.1097/MD.0000000000038063.

References
1.
Steensma M, Boland P, Morris C, Athanasian E, Healey J . Endoprosthetic treatment is more durable for pathologic proximal femur fractures. Clin Orthop Relat Res. 2011; 470(3):920-6. PMC: 3270160. DOI: 10.1007/s11999-011-2047-z. View

2.
Harvey N, Ahlmann E, Allison D, Wang L, Menendez L . Endoprostheses last longer than intramedullary devices in proximal femur metastases. Clin Orthop Relat Res. 2011; 470(3):684-91. PMC: 3270182. DOI: 10.1007/s11999-011-2038-0. View

3.
Schulman K, Kohles J . Economic burden of metastatic bone disease in the U.S. Cancer. 2007; 109(11):2334-42. DOI: 10.1002/cncr.22678. View

4.
Junnila M, Laaksonen I, Eskelinen A, Pulkkinen P, Havelin L, Furnes O . Implant survival of the most common cemented total hip devices from the Nordic Arthroplasty Register Association database. Acta Orthop. 2016; 87(6):546-553. PMC: 5119435. DOI: 10.1080/17453674.2016.1222804. View

5.
Janssen S, Kortlever J, Ready J, Raskin K, Ferrone M, Hornicek F . Complications After Surgical Management of Proximal Femoral Metastasis: A Retrospective Study of 417 Patients. J Am Acad Orthop Surg. 2016; 24(7):483-94. DOI: 10.5435/JAAOS-D-16-00043. View